Secondary prevention of coronary heart disease: How effective is modern therapy?;Sekundärprävention der koronaren herzkrankheit: Wie wirksam sind die modernen behandlungsmethoden?

Deutsche Medizinische Wochenschrift

Volumn 128, Issue 36, 2003, Pages 1849-1853

  Kolenda, Klaus Dieter ^a,b  

^a Klini1ki Centar Univerziteta u Sarajevu   (Germany)

^b Ostseeklinik Schönberg Holm ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTITHROMBOCYTIC AGENT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA CAROTENE; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; EPIDEMIOLOGICAL DATA; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; REVIEW; SECONDARY PREVENTION; THROMBOCYTE AGGREGATION INHIBITION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTILIPEMIC AGENTS; COMBINED MODALITY THERAPY; CONTROLLED CLINICAL TRIALS; CORONARY ARTERY BYPASS; CORONARY DISEASE; EXERCISE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE STYLE; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RELAXATION TECHNIQUES; RISK FACTORS; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 0141502362     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-41970     Document Type: Review

References (34)

1. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. 1: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106
2. Blumenthal JA, Jiang W, Babyok MA et al. Stress management and exercise training in cardial patients with myocardial ischemia. Arch Intern Med 1997; 157: 2213-2223
3. De Longeril M, Salem P, Martin JL et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction. Final report of the Lyon Diet Heart Study. Circulation 1999; 99: 779-785
4. Diel H. Reversing coronary heart disease. Totowa-New Yersey: Humana Press, In: Temple NJ, Burkett DP, editors. Western diseases - their dietary prevention and reversibility. 1994: 237-316
5. Greenhalgh T. Einführung in die Evidence-based medicine. Verlag Hans Huber, Bern-Göttingen-Toronto-Seattle, 2000: 231
6. Haskell WE, Alderman EL, Fair JM et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardial events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994; 89: 975-990
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22
8. Jaeschke R. Therapy and understanding the results. AMA press, Chicago, In: Guyatt G, Ronné D (eds.). User's guide of the medical literature. 2002
9. Kolenda KD. Die koronare Herzkrankheit: Wie wirken sich Veränderungen des Lebensstils aufden Behandlungserfolg aus? intern prax 2002; 42: 695-708
10. Kolenda KD. Ernährungstherapie bei der Rehabilitation von Patienten mit koronarer Herzkrankheit. intern prax 1997; 37: 701-720
11. Kolenda KD, Maurer S. Sport und Bewegungstherapie in stationären und ambulanten Herzgruppen in Abhängigkeit von Belastung und Belastbarkeit. intern prax 1999: 39: 467-480
12. Kreuzer J, Kübler W. Sekundärprävention nach Herzinfarkt - therapeutische Effizienz-Kosten-Nutzen-Relation. Internist 2001; 42: 713-719
13. Kunz R, Ollenschläger G, Raspe H et al. Lehrbuch Evidenzbasierte Medizin in Klinik und Praxis. Deutscher Ärzteverlag Köln, 2000: 128-132
14. Leon AS, Conetti I, Jacobs DR, Rauramaa R. Leisure time, physical activity levels and risk of coronary heart disease and death. The Multiple-Risk-Factor-Intervention Trial. JAMA 1987; 258: 2388-2395
15. Linden W, Stossel C, Maurice I. Psychosocial interventions for patients with coronary artery disease. A metaanalysis. Arch Intern Med 1996; 156: 745-752
16. Lipid Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of cholesterol levels. N Engl J Med 1998; 339: 1349-1357
17. Meyer FW. Statine in der Sekundär- und Primärprävention der koronaren Herzkrankheit? intern prax 1999; 39: 849-858
18. Morrison LM. Reduction of mortality-rate in coronary atherosclerosis by low cholesterol, low fat diet. Am Heart J 1951; 42: 538-554
19. Morrison LM. Diet in coronary atherosclerosis. JAMA 1960; 173: 884-888
20. Niebauer J, Hambrecht R, Marburger C et al. Fettarme Diät und körperliches Training bei koronarer Herzkrankheit - Langzeitergebnisse der Sekundärprävention. Dtsch Med Wochenschr 1994; 119: 7-12
21. O'Connor GT, Buring IE, Yusuf S et al. An overview of randomised trials of rehabilitation with exercise after myocardial infarction. Circulation 1989; 80: 234-244
22. Ornish D, Brown SE, Scherwitz LW et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990; 336: 129-134
23. Ornish D, Scherwitz LW, Bellings JH et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA 1998; 280: 2001-2007
24. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669-677
25. Rautenstrauch I. Evidence-based medicine: Wie verlässlich sind die Beobachtungsstudien? Dtsch Med Wochenschr 2000; 125: A13-A14
26. RITA-2-trial participants. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. Lancet 1997; 350: 461-468
27. Rozanski A, Blumenthal JA, Kaplan I. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999; 99: 2192-2217
28. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009
29. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389
30. Sellmayer A, Theissen K, Weber PC. Omega-3-Fettsäuren nach Myokardinfarkt: Senkung der Mortalität durch antiarrhythmische Effekte. Dtsch Med Wochenschr 2000; 125: 1542-1546
31. Sudlow C, Baigent C, Lonn E et al. Sekundärprävention koronarischämischer Komplikationen. Verlag Hans Huber, Bern-Gö ttingen-Toronto-Seattle, In: Godlee F (Hrsg). Clinical Evidence. Die besten Studien für die beste klinische Praxis. 2000: 67-99
32. Wilson K, Gibson N, Willan A, Cook D. Effect of smoking cessation on mortality after myocardial infarction. Arch Int Med 2000; 160: 939-944
33. Yusuf S, Wittes I, Friedman L. Overview of results of randomised clinical trials in heart disease. 1. Treatment following myocardial infarction. JAMA 1988; 260: 2088-2093
34. Yusuf S, Zucker D, Peduzzi P et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the coronary artery bypass surgery trialists collaboration. Lancet 1994; 344: 563-570